Precipio Cleans Up Balance Sheet, Repays $1.1M Loan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Precipio has made strides in cleaning up its balance sheet with two accomplishments: A $1.1M advance from Change Healthcare has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate principal amount of $80,000. Other than this minor loan, Precipio has a debt-free balance sheet. As part of a 2023 financing, the Company issued warrants to participating investors. In Q3 and Q4 of 2025, a portion of those warrants were exercised in normal manner, and the remainder were exercised cashless to reduce dilution to shareholders. At this point, all financial warrants have been exercised, and Precipio has no further financial warrants outstanding. Remaining are 10,000 warrants given to a vendor for services provided in 2022 in lieu of cash payment, at a strike price of $60, and expiring February 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRPO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRPO
About PRPO
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Precipio Reports Q1 Financial Results with Revenue Growth
- Financial Overview: Precipio reported a net loss of $1.4 million in Q1, yet achieved revenue of $6.71 million, reflecting a 36.1% year-over-year growth that indicates the company's potential for market expansion.
- Revenue Growth Drivers: The significant revenue increase is primarily attributed to the launch of new products and heightened market demand, which not only enhances the company's competitive position but also lays the groundwork for future profitability.
- Market Performance Analysis: Within the healthcare sector, Precipio's performance stands out, particularly among companies with a market cap of up to $2 billion, demonstrating its appeal to investors.
- Historical Financial Data Reference: Analyzing Precipio's historical financial data reveals trends in revenue and losses, providing crucial insights for investors' decision-making processes.
See More
Precipio Management Stock Options Vesting Announcement
- Stock Options Vesting: Precipio, Inc. announced that the management stock options granted in 2025 vested last week due to a more than 400% increase in the company's stock price since the grant, demonstrating strong stock performance and alignment of management and shareholder interests.
- Market-Based Vesting Structure: Unlike the standard four-year time-based vesting, management agreed to a market-based vesting structure requiring the stock price to exceed a 10-day VWAP of $30.30 for full vesting, designed to incentivize management to drive stock price growth.
- 2026 Option Grant: At the end of 2025, management agreed to a similar market-based structure for the 2026 stock option grant, setting a target price of $40, requiring a 68% increase in stock price for vesting, further reinforcing management incentives.
- Non-Cash Compensation Expense: As part of the accounting for the 2026 management stock option grant, the company booked an $800,000 non-cash stock compensation expense in Q1, impacting net loss and reflecting financial decisions in incentivizing management.
See More
Precipio to Host Q1 2026 Shareholder Update Call
- Shareholder Call Scheduled: Precipio will host its Q1 2026 shareholder update call on May 18, 2026, at 5 PM ET, incorporating a dedicated live Q&A session for the first time, aimed at enhancing transparency and shareholder engagement, thereby improving investor understanding of the company's strategy and performance.
- Interactive Q&A Session: The call will feature management remarks followed by a live Q&A, where investors can submit questions in advance via email, demonstrating the company's commitment to addressing investor feedback, which may bolster investor confidence.
- Company Mission and Vision: Precipio focuses on cancer diagnostics, aiming to tackle the issue of cancer misdiagnoses by developing high-accuracy diagnostic products and services that improve laboratory workflows and patient outcomes, thereby reducing healthcare costs and highlighting the company's strategic importance in the healthcare sector.
- Enhanced Information Transparency: The company communicates with investors through its website and social media, ensuring timely dissemination of all material information, which enhances transparency and may attract more investor interest and participation, further driving company growth.
See More
Precipio Reports FY 2025 Financial Results
- Financial Highlights: Precipio reported a FY 2025 GAAP EPS of -$0.23, indicating ongoing challenges but also a commitment to improving financial management.
- Revenue Growth: The company achieved revenues of $24.05 million, reflecting a robust year-over-year increase of 29.8%, showcasing its competitive position and rising customer demand in the market.
- Market Performance: Despite the negative EPS, the strong revenue growth may attract investor interest, potentially leading to a rebound in stock price in the future.
- Strategic Outlook: Precipio's financial results highlight its potential within the industry, suggesting that further market expansion and product innovation could pave the way for a shift towards profitability.
See More
Major Earnings Expected: Precipio (PRPO)
- Earnings Release Preview: Precipio (PRPO) is set to report earnings after the bell on Thursday, with market participants keenly anticipating its performance, which is expected to have a direct impact on the company's stock price.
- Market Reaction Expectations: Investors are adopting a cautious stance towards Precipio's earnings, with analysts generally believing that the results will reflect the company's adaptability in the current economic environment, potentially influencing future investment decisions.
- Earnings Season Schedule: This earnings release is a significant part of the earnings season, and Precipio's performance will provide the market with the latest insights into the biotechnology sector, aiding investors in assessing industry trends.
- Investor Focus: As the earnings date approaches, market attention on Precipio is increasing, with investors closely monitoring its revenue, profits, and future outlook to gauge the company's performance in a highly competitive market.
See More
Precipio Reports Preliminary Financials for FY 2025
- Significant Revenue Growth: Precipio's revenue surged from $18.5 million in 2024 to $24.0 million in 2025, marking a 30% year-over-year increase, which underscores the company's strong market demand and expansion capabilities in cancer diagnostics.
- Improved Adjusted EBITDA: The company reported an Adjusted EBITDA of $1.23 million for FY 2025, a substantial recovery from a loss of $1.5 million in 2024, indicating significant progress in profitability and operational efficiency.
- Positive Cash Flow Performance: Precipio achieved a positive operating cash flow of $688,000 for 2025, up from $439,000 in 2024, reflecting effective financial management and resource allocation.
- Increased Shareholder Value: CEO Ilan Danieli noted that 2025 was a stellar year for the company, with shareholder value tripling, demonstrating confidence in long-term investments and strategic growth initiatives.
See More
Precipio Reports Q1 Financial Results with Revenue Growth
- Financial Overview: Precipio reported a net loss of $1.4 million in Q1, yet achieved revenue of $6.71 million, reflecting a 36.1% year-over-year growth that indicates the company's potential for market expansion.
- Revenue Growth Drivers: The significant revenue increase is primarily attributed to the launch of new products and heightened market demand, which not only enhances the company's competitive position but also lays the groundwork for future profitability.
- Market Performance Analysis: Within the healthcare sector, Precipio's performance stands out, particularly among companies with a market cap of up to $2 billion, demonstrating its appeal to investors.
- Historical Financial Data Reference: Analyzing Precipio's historical financial data reveals trends in revenue and losses, providing crucial insights for investors' decision-making processes.
See More
Precipio Management Stock Options Vesting Announcement
- Stock Options Vesting: Precipio, Inc. announced that the management stock options granted in 2025 vested last week due to a more than 400% increase in the company's stock price since the grant, demonstrating strong stock performance and alignment of management and shareholder interests.
- Market-Based Vesting Structure: Unlike the standard four-year time-based vesting, management agreed to a market-based vesting structure requiring the stock price to exceed a 10-day VWAP of $30.30 for full vesting, designed to incentivize management to drive stock price growth.
- 2026 Option Grant: At the end of 2025, management agreed to a similar market-based structure for the 2026 stock option grant, setting a target price of $40, requiring a 68% increase in stock price for vesting, further reinforcing management incentives.
- Non-Cash Compensation Expense: As part of the accounting for the 2026 management stock option grant, the company booked an $800,000 non-cash stock compensation expense in Q1, impacting net loss and reflecting financial decisions in incentivizing management.
See More
Precipio to Host Q1 2026 Shareholder Update Call
- Shareholder Call Scheduled: Precipio will host its Q1 2026 shareholder update call on May 18, 2026, at 5 PM ET, incorporating a dedicated live Q&A session for the first time, aimed at enhancing transparency and shareholder engagement, thereby improving investor understanding of the company's strategy and performance.
- Interactive Q&A Session: The call will feature management remarks followed by a live Q&A, where investors can submit questions in advance via email, demonstrating the company's commitment to addressing investor feedback, which may bolster investor confidence.
- Company Mission and Vision: Precipio focuses on cancer diagnostics, aiming to tackle the issue of cancer misdiagnoses by developing high-accuracy diagnostic products and services that improve laboratory workflows and patient outcomes, thereby reducing healthcare costs and highlighting the company's strategic importance in the healthcare sector.
- Enhanced Information Transparency: The company communicates with investors through its website and social media, ensuring timely dissemination of all material information, which enhances transparency and may attract more investor interest and participation, further driving company growth.
See More
Precipio Reports FY 2025 Financial Results
- Financial Highlights: Precipio reported a FY 2025 GAAP EPS of -$0.23, indicating ongoing challenges but also a commitment to improving financial management.
- Revenue Growth: The company achieved revenues of $24.05 million, reflecting a robust year-over-year increase of 29.8%, showcasing its competitive position and rising customer demand in the market.
- Market Performance: Despite the negative EPS, the strong revenue growth may attract investor interest, potentially leading to a rebound in stock price in the future.
- Strategic Outlook: Precipio's financial results highlight its potential within the industry, suggesting that further market expansion and product innovation could pave the way for a shift towards profitability.
See More
Major Earnings Expected: Precipio (PRPO)
- Earnings Release Preview: Precipio (PRPO) is set to report earnings after the bell on Thursday, with market participants keenly anticipating its performance, which is expected to have a direct impact on the company's stock price.
- Market Reaction Expectations: Investors are adopting a cautious stance towards Precipio's earnings, with analysts generally believing that the results will reflect the company's adaptability in the current economic environment, potentially influencing future investment decisions.
- Earnings Season Schedule: This earnings release is a significant part of the earnings season, and Precipio's performance will provide the market with the latest insights into the biotechnology sector, aiding investors in assessing industry trends.
- Investor Focus: As the earnings date approaches, market attention on Precipio is increasing, with investors closely monitoring its revenue, profits, and future outlook to gauge the company's performance in a highly competitive market.
See More
Precipio Reports Preliminary Financials for FY 2025
- Significant Revenue Growth: Precipio's revenue surged from $18.5 million in 2024 to $24.0 million in 2025, marking a 30% year-over-year increase, which underscores the company's strong market demand and expansion capabilities in cancer diagnostics.
- Improved Adjusted EBITDA: The company reported an Adjusted EBITDA of $1.23 million for FY 2025, a substantial recovery from a loss of $1.5 million in 2024, indicating significant progress in profitability and operational efficiency.
- Positive Cash Flow Performance: Precipio achieved a positive operating cash flow of $688,000 for 2025, up from $439,000 in 2024, reflecting effective financial management and resource allocation.
- Increased Shareholder Value: CEO Ilan Danieli noted that 2025 was a stellar year for the company, with shareholder value tripling, demonstrating confidence in long-term investments and strategic growth initiatives.
See More
